PDX Core
Baylor College Of Medicine, Houston TX
Investigators
Linked publications, trials & patents
Abstract
Project Summary It is well-established that there are significantly higher mortality rates for a number of cancers in African Americans and other racial and ethnic minorities in the US. Despite overall reductions in cancer mortality in the last several decades, these disparities persist. The lack of appropriate models has been a serious issue in addressing these cancer health disparities. This Core is a collaboration between Baylor College of Medicine (BCM) and MD Anderson Cancer Center (MDACC). The PDX Core will recruit minority patients with cancer at BCM clinical sites to donate blood for circulating tumor cells (CTCs) or cancer tissues for establishment of patient derived xenografts (PDXs). The major focus will be on African American (AA) men with prostate cancer (PC). Dr Navone at MDACC has a unique, proven expertise in establishing PDXs from PC CTCs and tissues and she will establish the PC PDXs in her laboratory. These will be transferred to the BCM site of the PDX Core for additional characterization, transfer to the NCI PDTC PDX Repository and for experiments as part of Research Project 1 in this U54 submission. A secondary goal of the PDX Core will be to establish PDXs from minority patients at BCM clinical sites other than PC or breast cancer (BC), with a focus on cancers disparately affecting minority populations. This will be done at the BCM PDX Core. After establishment, these will be transferred to NCI PDTC PDX Repository to enhance minority PDX representation in this repository. The third goal will be to set up breast cancer (BC) PDXs for experiments in Research Project 2. These will be received from Drs. Lewis and Ellis here at BCM from their existing PDXs as well as new PDXs generated over the course of this proposal. The BC PDX establishment effort is separately funded and no additional BC PDXs will be generated by this PDX Core. Finally, in future years we will participate as requested in new transnetwork initiatives and pilot projects.
View original record on NIH RePORTER →